Summary

It is the industry analysis specialist’s new report, “Dyslipidemia - Drug Pipeline Analysis and Market Forecasts to 2016"" is an essential source of information and analysis on the global dyslipidemia market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by its team of industry experts.

Scope

The scope of the report includes:
- Annualized global dyslipidemia market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Geographies covered in this report are the US, the UK, Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data split across different phases, mechanism of action being developed and emerging trends. The key classes of mechanism of action include combination therapies, CETP inhibitors, MTP inhibitors, PPAR agonists, thyroid hormone receptor modulators, gene therapies, nicotinic acid receptor agonists, AMPK modulators, enzyme inhibitors, cholesterol absorption inhibitors, farsenyl X receptor agonists, prostacyclin release stimulators, CB1 receptor agonists, A1 adenosine receptor agonists and omega-3 fatty acid derivatives.
- Analysis of the current and future market competition in the global dyslipidemia market. The key future market players covered are AstraZeneca PLC, Abbott Laboratories, Merck & Co., GenFit, Aegerion Pharmaceuticals, Inc., Amarin Corporation Plc, Pfizer Inc., and F. Hoffman-La Roche.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- The key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future dyslipidemia market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global dyslipidemia market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global dyslipidemia market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global dyslipidemia market landscape? – Identify, understand and capitalize.

Company Mentioned
AstraZeneca PLC
Abbott Laboratories
Merck & Co.
GenFit
Aegerion Pharmaceuticals, Inc.
Amarin Corporation Plc
Pfizer Inc.
Roche

1
1 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Global Dyslipidemia Market: Market Characterization 6
2.1 Overview 6
2.2 Dyslipidemia Market Size 6
2.3 Dyslipidemia Market Forecast and CAGR 6
2.4 Drivers and Barriers for Dyslipidemia Market 7
2.4.1 Drivers for Dyslipidemia Market 8
2.4.2 Barriers for Dyslipidemia Market 8
2.5 Opportunity and Unmet Need 9
2.6 Key Takeaway 10
3 Dyslipidemia Market: Competitive Assessment 12
3.1 Overview 12
3.2 Strategic Competitor Assessment 12
3.3 Product Profile for the Major Marketed Products in Dyslipidemia Market 13
3.3.1 Lipitor (atorvastatin calcium) 13
3.3.2 Vyotrin (ezetimibe/simvastatin) 14
3.3.3 Zetia (ezetimibe) 15
3.3.4 Trilipix (fenofibric acid) 17
3.3.5 Simcor (simvastatin/niacin extended release tablets) 18
3.3.6 Lescol (fluvastatin sodium) 19
3.3.7 Livalo (pitavastatin calcium) 21
3.3.8 Lovaza (omega-3-acid ethyl esters) 22
3.4 Key Takeaway 26
4 Dyslipidemia Market: Pipeline Assessment 27
4.1 Overview 27
4.2 Strategic Pipeline Assessment 27
4.2.1 Technology Trends Analytic Framework 27
4.3 Dyslipidemia Therapeutics – Promising Drugs under Clinical Development 29
4.4 Molecule Profile for Promising Drugs for Dyslipidemia Under Clinical Development 33
4.4.1 Cetriad (rosuvastatin/fenofibric acid, ABT-335) 33
4.4.2 ABT335 (SLV348, Trilipix) + simvastatin or atorvastatin 34
4.4.3 RG1658 (Dalcetrapib, JTT-705, RO4607381) 35
4.4.4 MK-0524A (Cordaptive, niacin + laropiprant) 36
4.4.5 Caduet (amlodipine + atorvastatin) 37
4.4.6 GFT505 39
4.4.7 AEGR-733 (lopitamide, BMS-201038) 40
4.4.8 AMR101 (LAX-101, Miraxion) 41
4.4.9 MK-0859 (anacetripib) 42
4.5 Dyslipidemia Therapeutics Market – Clinical Pipeline by Mechanism of Action 43
4.6 Dyslipidemia Pipeline – Pipeline by Clinical Phases of Development 44
4.6.1 Dyslipidemia Therapeutics – Phase III Clinical Pipeline 44
4.6.2 Dyslipidemia Therapeutics – Phase II Clinical Pipeline 46
4.6.3 Dyslipidemia Therapeutics – Phase I Clinical Pipeline 47
4.6.4 DyslipidemiaTherapeutics – Preclinical Pipeline 48
4.6.5 DyslipidemiaTherapeutics – Discovery Pipeline 48
4.7 Discontinued / Suspended Drug for Dyslipidemia 48
4.8 Key Takeaway 51
5 Dyslipidemia Market: Implications for Future Market Competition 52
6 Dyslipidemia Market: Future Players in the Dyslipidemia Market 54
6.1 Introduction 54
6.1.1 AstraZeneca PLC 54
6.1.2 Overview 54
6.1.3 Cardiovascular Disease Portfolio 55
6.1.4 Dyslipidemia Product Portfolio 55
6.2 Abbott Laboratories 57
6.2.1 Overview 57
6.2.2 Cardiovascular Disease Portfolio 58
6.2.3 Dyslipidemia Product Portfolio 58
6.3 Merck & Co. 60
6.3.1 Overview 60
6.3.2 Cardiovascular Disease Portfolio 61
6.3.3 Cardiovascular Product Portfolio 61
6.4 GenFit 64
6.4.1 Overview 64
6.4.2 Cardiovascular Disease Portfolio 65
6.4.3 Cardiovascular Product Portfolio 65
6.5 Aegerion Pharmaceuticals, Inc. 66
6.5.1 Overview 66
6.5.2 Cardiovascular Disease Portfolio 66
6.5.3 Dyslipidemia Product Portfolio 66
6.6 Amarin Corporation Plc 68
6.6.1 Overview 68
6.6.2 Cardiovascular Disease Portfolio 68
6.6.3 Dyslipidemia Product Portfolio 69
6.7 Pfizer Inc. 69
6.7.1 Overview 69
6.7.2 Dyslipidemia Product Portfolio 71
6.8 Roche 72
6.8.1 Overview 72
6.8.2 Dyslipidemia Product Portfolio 73
7 Dyslipidemia Market: Appendix 75
7.1 Market Definitions 75
7.2 Abbreviations 75
7.3 Research Methodology 76
7.3.1 Coverage 77
7.3.2 Secondary Research 77
7.3.3 Forecasting 78
7.3.4 Primary Research 81
7.3.5 Expert Panels 81
7.4 Contact Us 81
7.5 Disclaimer 81
7.6 Sources 82

1.1 List of Tables
Table 1: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2001-2009 7
Table 2: Global Dyslipidemia Therapeutics Market, Revenue Forecasts ($bn), 2009-2016 7
Table 3: Major Marketed Products Comparison in the Dyslipidemia Market, 2010 24
Table 4: Dyslipidemia Therapeutics – Most Promising Drugs Under Clinical Development, 2010 29
Table 5: Dyslipidemia Therapeutics – Phase III Clinical Pipeline, 2010 44
Table 6: Dyslipidemia Therapeutics – Phase II Clinical Pipeline, 2010 46
Table 7: Dyslipidemia Therapeutics – Phase I Clinical Pipeline, 2010 47
Table 8: Dyslipidemia Therapeutics – Preclinical Pipeline, 2010 48
Table 9: Dyslipidemia Therapeutics – Discovery Pipeline, 2010 48
Table 10: List of Discontinued Drugs for Dyslipidemia, 2010 48
Table 11: AstraZeneca PLC–Cardiovascular Pipeline Products, 2010 55
Table 12: Abbott Laboratories–Cardiovascular Pipeline Products, 2010 58
Table 13: Merck & Co. – Cardiovascular Disease Pipeline Products, 2010 61
Table 14: GenFit -Cardiovascular Disease Pipeline Products, 2010 65
Table 15: Aegerion Pharmaceuticals, Inc.- Cardiovascular Disease Pipeline Products, 2010 66
Table 16: Amarin Corporation Plc.– Cardiovascular Disease Pipeline Products, 2010 68
Table 17: Pfizer Inc. – Cardiovascular Disease Pipeline Products, 2010 70
Table 18: Roche – Cardiovascular Disease Pipeline Products, 2010 73"

1.2 List of Figures
Figure 1: Global Dyslipidemia Therapeutics Market, Revenue ($bn), 2001–2009 6
Figure 2: Global Dyslipidemia Market Revenue ($bn), 2009-2016 7
Figure 3: Opportunity and Unmet Need in the Dyslipidemia Market, 2010 10
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Dyslipidemia, 2010 13
Figure 5: Technology Trends Analytic Framework of the Dyslipidemia Pipeline, 2010 28
Figure 6: Technology Trends Analytic Framework of the Dyslipidemia Pipeline – Description, 2010 28
Figure 7: Dyslipidemia Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 43
Figure 8: Dyslipidemia Pipeline by Phase of Clinical Development, 2010 44
Figure 9: Implications for Future Market Competition in the Dyslipidemia Market, 2010 52
Figure 10: Dyslipidemia Therapeutics Market – Clinical Pipeline by Company, 2010 54
Figure 11: GlobalData Methodology, 2010 77
Figure 12: GlobalData Market Forecasting Model 80.

Keywards

Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action.